Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation
Autor: | Marcus Celik Hansen, Maja Ludvigsen, Ina Kathrine Lykke Ewald, G. Kerndrup, Johannes Frasez Soerensen, Marie Bill, Peter Hokland, Lene Hyldahl Ebbesen, Anne Stidsholt Roug, Carina A. Rosenberg, Anni Aggerholm |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Oncology
medicine.medical_specialty Myeloid Neoplasia Myeloid business.industry Hematopoietic Stem Cell Transplantation CD34 Neoplasms Second Primary Hematology Leukapheresis Transplantation Autologous Haematopoiesis Autologous stem-cell transplantation medicine.anatomical_structure Immunophenotyping Case-Control Studies Internal medicine Humans Medicine Bone marrow Clonal Hematopoiesis Stem cell business |
Zdroj: | Soerensen, J F, Aggerholm, A, Kerndrup, G B, Hansen, M C, Ewald, I K L, Bill, M, Ebbesen, L H, Rosenberg, C A, Hokland, P, Ludvigsen, M & Stidsholt Roug, A 2020, ' Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation ', Blood advances, vol. 4, no. 5, pp. 885-892 . https://doi.org/10.1182/bloodadvances.2019001157 Soerensen, J F, Aggerholm, A, Kerndrup, G B, Hansen, M C, Ewald, I K L, Bill, M, Ebbesen, L H, Rosenberg, C A, Hokland, P, Ludvigsen, M & Stidsholt Roug, A 2020, ' Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation ', Blood Advances, vol. 4, no. 5, pp. 885-892 . https://doi.org/10.1182/bloodadvances.2019001157 |
DOI: | 10.1182/bloodadvances.2019001157 |
Popis: | Therapy-related myeloid neoplasms (tMN) develop after exposure to cytotoxic and radiation therapy, and due to their adverse prognosis, it is of paramount interest to identify patients at high risk. The presence of clonal hematopoiesis has been shown to increase the risk of developing tMN. The value of analyzing hematopoietic stem cells harvested at leukapheresis before autologous stem cell transplantation (ASCT) with next-generation sequencing and immunophenotyping represents potentially informative parameters that have yet to be discovered. We performed a nested case-control study to elucidate the association between clonal hematopoiesis, mobilization potential, and aberrant immunophenotype in leukapheresis products with the development of tMN after ASCT. A total of 36 patients with nonmyeloid disease who were diagnosed with tMN after treatment with ASCT were included as case subjects. Case subjects were identified from a cohort of 1130 patients treated with ASCT and matched with 36 control subjects who did not develop tMN after ASCT. Case subjects were significantly poorer mobilizers of CD34+ cells at leukapheresis (P = .016), indicating that these patients possess inferior bone marrow function. Both clonal hematopoiesis (odds ratio, 5.9; 95% confidence interval, 1.8-19.1; P = .003) and aberrant expression of CD7 (odds ratio, 6.6; 95% confidence interval, 1.6-26.2; P = .004) at the time of ASCT were associated with an increased risk of developing tMN after ASCT. In conclusion, clonal hematopoiesis, present at low variant allele frequencies, and aberrant CD7 expression on stem cells in leukapheresis products from patients with nonmyeloid hematologic cancer hold potential for the early identification of patients at high risk of developing tMN after ASCT. |
Databáze: | OpenAIRE |
Externí odkaz: |